AbbVie Inc. (ABBV)

NYSE: ABBV · IEX Real-Time Price · USD
+0.72 (0.53%)
Jun 5, 2023, 12:41 PM EDT - Market open
Market Cap 242.80B
Revenue (ttm) 56.74B
Net Income (ttm) 7.59B
Shares Out 1.76B
EPS (ttm) 4.24
PE Ratio 32.42
Forward PE 14.39
Dividend $5.92 (4.30%)
Ex-Dividend Date Apr 13, 2023
Volume 1,225,969
Open 137.00
Previous Close 136.87
Day's Range 136.94 - 138.31
52-Week Range 131.10 - 168.11
Beta 0.55
Analysts Buy
Price Target 164.94 (+19.88%)
Earnings Date Jul 28, 2023

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with C... [Read more]

Sector Healthcare
CEO Richard A. Gonzalez
Employees 50,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2022, AbbVie's revenue was $58.05 billion, an increase of 3.30% compared to the previous year's $56.20 billion. Earnings were $11.84 billion, an increase of 2.55%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $164.94, which is an increase of 19.88% from the latest price.

Price Target
(19.88% upside)
Analyst Consensus: Buy
Stock Forecasts


Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

-  At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE...

5 days ago - PRNewsWire

Should You Pick AbbVie Stock Over LLY?

Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices.

Other symbols: LLY
1 week ago - Forbes

Best Retirement Stocks to Buy Now

The best retirement stocks ideally have high dividend yields that can be sustained. This can lead to steady income and long-term value for retirees.

1 week ago - Kiplinger

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease

NORTH CHICAGO, Ill. , May 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, ...

1 week ago - PRNewsWire

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

-  Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination with methotrexate (MTX), are reported for adult pati...

1 week ago - PRNewsWire

Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health (NYSE:CVS), AbbVie (NYSE:ABBV)

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: CVSJNJ
1 week ago - Benzinga

US FDA approves Genmab-AbbVie's blood cancer therapy

The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment...

Other symbols: GMAB
2 weeks ago - Reuters

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NORTH CHICAGO, Ill. , May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only...

2 weeks ago - PRNewsWire

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

–  The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib...

2 weeks ago - PRNewsWire

SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval


3 weeks ago - PRNewsWire

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

-  Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ®) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational us...

1 month ago - PRNewsWire

Top Ancillary And Medical Marijuana Stocks In May 2023

Are These Cannabis Stocks Good Long-Term Positions? The post Top Ancillary And Medical Marijuana Stocks In May 2023 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Buddi...

Other symbols: SMG
1 month ago - MarijuanaStocks

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill. , May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023.

1 month ago - PRNewsWire

Drugmakers brace for serious headwinds ahead

Yahoo Finance's Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching ...

Other symbols: LLYMRK
1 month ago - Yahoo Finance

AbbVie stock falls toward a 6-week low after adjusted profit fell short of expectations, but the full-year outlook was raised

Shares of AbbVie Inc. ABBV dove 6.2% toward a six-week low in premarket trading Thursday, after the biopharmaceutical company missed first-quarter profit expectations but lifted its full-year outlook....

1 month ago - Market Watch

AbbVie Reports First-Quarter 2023 Financial Results

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 ...

1 month ago - PRNewsWire

Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase

CHICAGO--(BUSINESS WIRE)---- $ABBV #bigpharma--Consumers sued AbbVie alleging it fraudulently inflated the cost of Humira by 470% over the last two decades, according to attorneys at Hagens Berman.

1 month ago - Business Wire

AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional o...

1 month ago - PRNewsWire

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) f...

1 month ago - PRNewsWire

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

A significantly higher proportion of patients treated with RINVOQ achieved the co-primary endpoints of endoscopic response and clinical remission and the key secondary endpoint of corticosteroid-free ...

1 month ago - PRNewsWire

AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year

NORTH CHICAGO, Ill. , April 12, 2023 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF...

1 month ago - PRNewsWire

Final Trades: Starbucks, Abbvie, Microsoft & APA Corp.

The final trades of the day. With CNBC's Melissa Lee and the Fast Money traders.

Other symbols: MSFTSBUXAPA
1 month ago - CNBC Television

Abbvie lowers guidance after $150 million charge

Abbvie Inc. ABBV, +0.64% late Wednesday lowered its guidance for the year to include a charge of about $150 million. The pharma company said GAAP as well as adjusted earnings for its first quarter are...

2 months ago - Market Watch

Final Trades: Abbvie, Thermo Fisher & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: TMOIBB
2 months ago - CNBC Television

A Look at Bernard Horn's Top Holdings Ahead of Value Conference

With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in develo...

2 months ago - GuruFocus